Alkem Laboratories Ltd.

Financial

	Alkem Laboratories	Mankind Pharma	Cipla
Operational Metrics
Pharmaceutical Sector
Number of ANDA's Filed in USA	176.0 .	55.0 .	277.0 .
Number of ANDA's Approved By USFDA	145.0 .	32.0 .	196.0 .
Number of ANDA's Filed in Australia	42.0	n/a	n/a
Number of ANDA's Approved by Australia	32.0	n/a	n/a
Number of ANDA's Filed in Europe	18.0	n/a	n/a
Number of ANDA's Approved in Europe	12.0	n/a	n/a
Domestic Sales Growth - YoY	10.8 %	n/a	9.1 %
R&D as a % of Total Sales	6.0 %	2.15 %	7.2 %
Financials
5 yr Average ROE	16.74 %	23.48 %	11.43 %
5yr average Equity Multiplier	1.42	1.4	1.39
5yr Average Asset Turnover Ratio	0.9	1.02	0.76
5yr Avg Net Profit Margin	13.14 %	16.52 %	10.96 %
Price to Book	5.79	9.11	4.48
P/E	33.23	44.58	29.0
5yr Avg Cash Conversion Cycle	0.57 Days	-45.92 Days	-3.69 Days
Inventory Days	55.43 Days	60.23 Days	59.85 Days
Days Receivable	40.86 Days	19.33 Days	44.13 Days
Days Payable	116.85 Days	132.42 Days	114.64 Days
5yr Average Interest Coverage Ratio	24.09	47.23	23.71
5yr Avg ROCE	22.27 %	31.06 %	15.24 %
5yr Avg Operating Profit Margin	19.27 %	25.32 %	22.51 %
5 yr average Debt to Equity	0.22	0.07	0.13
5yr CAGR Net Profit	5.29 %	17.25 %	12.9 %
5yr Average Return on Assets	11.73 %	16.73 %	8.36 %
Shareholdings
Promoter Holding	56.74 %	74.88 %	33.47 %
Share Pledged by Promoters	0.0	0.0	0.0
Change in Promoter Holding (3 Yrs)	-3.42 %	-1.62 %	-3.26 %
Change in Mutual Fund Holding (3 Yrs)	5.03 %	6.74 %	2.19 %

Business

	Alkem Laboratories	Mankind Pharma	Cipla
Product Wise Break-Up	Product Wise Break-Up Pharmaceutical 100.0 Urology 0 Neuro/CNS 0 Pain/Analgesics 0 Gynaecology 0 Dermatology 0 Anti-Diabetic 0 Respiratory 0 VMN 0 Gastro - Intestinal 0 Cardiovascular 0 Anti-infectives 0 New ventures 0 Pharmaceuticals 0	Product Wise Break-Up Pain/Analgesics 4.0 Dermatology 5.0 Gastrointestinal 10.0 Pharmaceuticals 0 Cardiovascular 15.0 Anti-infectives 15.0 Gynaecology 8.0 Neuro/CNS 3.0 New ventures 0 Respiratory 9.0 Pharmaceutical 0 VMN 9.0 Urology 6.0 Anti-Diabetic 8.0 Others 8.0	Product Wise Break-Up Pain/Analgesics 0 Dermatology 0 Gastro - Intestinal 0 Pharmaceutical 96.57 Cardiovascular 0 Anti-infectives 0 Gynaecology 0 Neuro/CNS 0 New ventures 3.43 Respiratory 0 Pharmaceutical 0 VMN 0 Urology 0 Anti-Diabetic 0
Therapeutic Area Wise Break-Up - Domestic	Therapeutic Area Wise Break-Up - Domestic Anti-Infective 37.6 Gastro Intestinal 18.6 Pain Management 10.9 Vitamins / Minerals / Nutrients 10.3 Anti - Diabetes 4.0 Gynecology 4.0 Central Nervous System (CNS) 3.8 Respiratory 3.3 Derma 2.8 Cardiac Science 2.3 Urology 0 Antivirals 0 Neuro /CNS 0 Gynaec. 0 Vitamins 0 Antineoplast 0 Opthal/Otologicals 0 Oncology 0 Anti Diabetic 0 Others 2.4	-	Therapeutic Area Wise Break-Up - Domestic Derma 2.7 Oncology 0 Respiratory Systems 38.9 Antineoplast 0 Vitamins / Minerals / Nutrients 0 Pain Management 0 Anti-Infective 0 Ophthalmology 3.1 Anti - Diabetes 0 Urology 4.8 Gastro Intestinal 5.8 Central Nervous System (CNS) 0 Central Nervous System (CNS) 2.3 Cardiac Science 0 Vitamins 0 Anti - Diabetes 3.8 Antivirals 3.1 Gynaec. 0 Gynecology 0 Others 35.5
Location Wise Break-Up	Location Wise Break-Up India 67.18 USA 30.98 Nepal 0 Sri Lanka 0 Bangladesh 0 SAGA 0 Europe 0 Global API 0 Rest of the World 0 Emerging Markets 0 North America 0 Others 1.84	Location Wise Break-Up North America 0 SAGA 0 Bangladesh 0 USA 0 Sri Lanka 0 Rest of the World 0 Europe 0 Global API 0 Nepal 0 Emerging Markets 0 India 89.0 Others 11.0	Location Wise Break-Up North America 29.0 SAGA 12.0 Bangladesh 0 USA 0 Sri Lanka 0 Rest of the World 11.0 Europe 0 Global API 2.0 Nepal 0 Emerging Markets 0 India 44.0 Others 2.0
Asset Break-Up	Asset Break-Up India 85.09 USA 13.19 South Africa 0 Others 1.72	-	Asset Break-Up USA 30.05 South Africa 16.85 India 47.79 Others 5.31

Alkem Laboratories Ltd.

SIGN UP FOR FREE